Results 211 to 220 of about 9,890 (252)
Some of the next articles are maybe not open access.
2021
Corneal cross-linking was first introduced in 2003 as a novel approach to halt progression of corneal ectasia. Adopted early, and widely used abroad, the FDA approved a drug device combination product for corneal cross-linking in the United States in 2016.
Stephen Tse +2 more
openaire +1 more source
Corneal cross-linking was first introduced in 2003 as a novel approach to halt progression of corneal ectasia. Adopted early, and widely used abroad, the FDA approved a drug device combination product for corneal cross-linking in the United States in 2016.
Stephen Tse +2 more
openaire +1 more source
Expert Review of Ophthalmology, 2014
Corneal collagen cross-linking (CXL) entails the use of ultraviolet light with a cross-linking agent to form cross bridges in the corneal collagen fibers with subsequent strengthening of the corneal stroma. CXL was first reported on humans in 2003 for patients with keratoconus.
Majed Alkharashi +2 more
openaire +1 more source
Corneal collagen cross-linking (CXL) entails the use of ultraviolet light with a cross-linking agent to form cross bridges in the corneal collagen fibers with subsequent strengthening of the corneal stroma. CXL was first reported on humans in 2003 for patients with keratoconus.
Majed Alkharashi +2 more
openaire +1 more source
Expanding indications for corneal cross-linking
Current Opinion in Ophthalmology, 2023Purpose of review The aim of this study was to summarize the recent developments in corneal cross-linking (CXL) and its indications, including corneal ectasias, refractive surgery and infectious keratitis. Recent findings Advances in CXL technology, such as the use of higher ...
Farhad, Hafezi +2 more
openaire +2 more sources
Customized Corneal Cross-Linking
2018Personalized accelerated crosslinking nomograms for the management of corneal ectasia were conceived after comparative analysis of demarcation lines and cell viability observed after customized accelerated epithelium-off crosslinking CXL treatments by spectral domain corneal OCT and scanning laser in vivo confocal microscopy matching all the clinical ...
Mazzotta C., Rechichi M., Ferrise M.
openaire +3 more sources
Corneal Infiltrates After Corneal Collagen Cross-Linking
Journal of Refractive Surgery, 2010Purpose: To present a case of advancing keratoconus treated with corneal collagen cross-linking (CXL) with ultraviolet A (UVA) light and riboflavin complicated with sterile infiltrates. Methods: The patient’s cornea was de-epithelialized and CXL was performed with ...
George F, Mangioris +5 more
openaire +2 more sources
Cornea, 2022
Abstract: When treating corneal ectasias, successful corneal cross-linking (CXL) requires three factors: riboflavin saturation of the corneal stroma, ultraviolet (UV) light, and oxygen. Riboflavin is too large to pass through epithelial tight junctions, so traditionally epithelial debridement is performed before riboflavin is applied making ...
openaire +2 more sources
Abstract: When treating corneal ectasias, successful corneal cross-linking (CXL) requires three factors: riboflavin saturation of the corneal stroma, ultraviolet (UV) light, and oxygen. Riboflavin is too large to pass through epithelial tight junctions, so traditionally epithelial debridement is performed before riboflavin is applied making ...
openaire +2 more sources
Corneal Collagen Cross-Linking Complications
Seminars in Ophthalmology, 2017Corneal cross-linking was approved by United States Food and Drug Administration for the treatment of progressive keratoconus in April 2016. As this approach becomes more widely used for the treatment of keratoconus and post-laser in situ keratomileusis (LASIK) ectasia, the medical community is becoming more familiar with potential complications ...
Charisma B, Evangelista +1 more
openaire +2 more sources
Corneal Cross Linking for Keratoconus
Seminars in Ophthalmology, 2010Riboflavin-induced ultraviolet light (UV) cross linking has received a significant amount of attention in recent years. It is currently approved in Europe as a treatment for keratoconus and is also being used for other corneal disorders. The goal of this paper is to review in detail seminal papers and studies that have been done to support cross ...
Anne, Keating +2 more
openaire +2 more sources
Accelerated Corneal Cross-Linking
2018Purpose: Corneal cross-linking (CXL) is a relatively new treatment that offers refractive stability in patients with corneal ectatic disorders. The conventional Dresden protocol has been firstly described, and its effectiveness has been demonstrated by several clinical trials.
Leopoldo Spadea +3 more
openaire +2 more sources
Riboflavin for corneal cross-linking
Drugs of Today, 2016Corneal collagen cross-linking (CXL) with riboflavin and ultraviolet A (UVA) radiation is the first therapeutic modality that appears to arrest the progression of keratoconus and other corneal ectasias. Riboflavin is central to the process, acting as a photosensitizer for the production of oxygen singlets and riboflavin triplets.
openaire +2 more sources